MedTrace Logo

Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients

NCT06685653 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2024-11-12

No results posted yet for this study

Summary

This is a phase IIT , it is an open-label study designed to evaluate the safety and tolerability of personalized mRNA tumor vaccine RGL-270 targeting tumor-specific neoantigens and Adebrelimab (a humanized PD-L1 monoclonal antibody) in patients with resectable NSCLC and those with NSCLC who have relapsed or metastasized after first-line standard therapy.

Conditions

Interventions

BIOLOGICAL

Adebrelimab+RGL-270

Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody. Drug: RGL-270 RGL-270 is a mRNA tumor vaccines

BIOLOGICAL

Adebrelimab+RGL-270/single RGL-270

Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody. Drug: RGL-270 RGL-270 is a mRNA tumor vaccines

Sponsors & Collaborators

  • Jilin Provincial Cancer Hospital

    collaborator UNKNOWN

  • Nanjing Tianyinshan Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2026-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06685653 on ClinicalTrials.gov